Identification and characterization of genes associated with human hepatocellular carcinogenesis

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4990-4996

  Kondoh, Nobuo ^a   Wakatsuki, Toru ^a   Akihide, Ryo ^b   Hada, Akiyuki ^a   Aihara, Tsukasa ^a   Horiuchi, Sankichi ^b   Goseki, Narihide ^b   Matsubara, Osamu ^a   Takenaka, Kenji ^c   Shichita, Mizue ^d   Tanaka, Kenji ^b   Shuda, Masahiro ^b   Yamamoto, Mikio ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OITA RED CROSS HOSPITAL   (Japan)

^d Fuji Yakuhin Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 REDUCTASE; GALECTIN; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; PHOSPHOPROTEIN; SOMATOMEDIN BINDING PROTEIN 1; VITRONECTIN;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CELL STRAIN HEPG2; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS;

ANTIGENS, SURFACE; CARCINOMA, HEPATOCELLULAR; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; GALECTIN 4; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HEMAGGLUTININS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; LECTINS; LIVER; LIVER NEOPLASMS; MEMBRANE PROTEINS; MIXED FUNCTION OXYGENASES; PHOSPHOPROTEINS; RIBOSOMAL PROTEINS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VITRONECTIN;

EID: 0033214697     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Farber, E., and Sarma, D. S. R. Biology of disease. Hepatocarcinogenesis: a dynamic cellular perspective. Lab. Investig., 56: 4-22, 1987.
2. Columbano, A., and Shinozuka, H. Liver regeneration versus direct hyperplasia. FASEB J., 10: 1118-1128, 1996.
3. Edamoto, Y., Tani, M., Kurata, T., and Abe, K. Hepatitis C, and B virus infections in hepatocellular carcinoma. Cancer (Phila.), 77: 1787-1791, 1996.
4. Choudhury, S., Krishna, M., and Bhattacharya, R. K. Activation of ras oncogenes during hepatocarcinogenesis induced by N-nitrosodiethylamine: possible involvement of PKC and GAP. Cancer Lett., 109: 149-154, 1996.
5. Stork, P., Loda, M., Bosari, S., Wiley, B., Poppenhusen, K., and Wolfe, H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene, 6: 857-862, 1991.
6. Cerutti, P., Hussain, P., Pourzand, C., and Aguilar, F. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res., 54 (Suppl.): 1934s-1938s, 1994.
7. Hayashi, S., Mori, I., Nonoyama, T., and Mitsumori, K. Point mutation of the c-H-ras gene in spontaneous liver tumors of transgenic mice carrying the human H-ras gene. Toxicol. Pathol., 26: 556-561, 1998.
8. Ogata, N., Kamimura, T., and Asakura, H. Point mutation, allelic loss and increased methylation of c-H-ras gene in human hepatocellular carcinoma. Hepatology, 13: 31-37, 1991.
9. Takada, S., and Koike, K. Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells. Oncogene, 4: 189-193, 1989.
10. Arbuthnot, P., Kew, M., Parker, I., and Fitschen, W. Expression of c-erbA in human hepatocellular carcinoma. Anticancer Res., 9: 885-887, 1989.
11. Boix, L., Rosa, J. L., Ventura, F., Castells, A., Bruix, J., Rodes, J., and Bartrons, R. C-met mRNA overexpression in human hepatocellular carcinoma. Hepatology, 19: 88-91, 1994.
12. Suzuki, K., Hayashi, N., Yamada, Y., Yoshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A., Kisida, Y., Kashiwagi, T., Fusamoto, H., and Kamada, T. Expression of the c-met proto-oncogene in human hepatocellular carcinoma. Hepatology, 20: 1231-1236, 1994.
13. Huber, B. E., and Thorgeirsson, S. S. Analysis of c-myc expression in a human hepatoma cell line. Cancer Res., 47: 3414-3420, 1987.
14. Tiniakos, D., Spandidos, D. A., Kakkanas, A., Pintzas, A., Pollice, L., and Tiniakos, G. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues. Anticancer Res., 9: 715-721, 1989.
15. Peng, S. Y., Lai, P. L., and Hus, H. C. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J. Formos. Med. Assoc., 92: 866-870, 1993.
16. Abou-Elella, A., Gramlich, T., Fritsch, C., and Gansler, T. C-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod. Pathol., 9: 95-98, 1996.
17. Zhang, X. K., Huang, D. P., Qui, D. K., and Chiu, J. F. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors. Oncogene, 5: 909-914, 1990.
18. Twu, J. S., Lai, M. Y., Chen, D. S., and Robinson, W. S. Activation of proto oncogene c-jun by the X protein of hepatitis B virus. Virology, 192: 346-350, 1993.
19. Hildt, E., Saher, G., Brass, V., and Hofschneider, P. H. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology, 225: 235-239, 1996.
20. Hosono, S., Lee, C. S., Chou, M. J., Yang, C. S., and Shih, C. H. Molecular analysis of the P53 alleles in primary hepatocellular carcinomas and cell lines. Oncogene, 6: 237-243, 1991.
21. Velculescu, V. E., Zhang, L., Vogelstein, B., and Kinzler, K. W. Serial analysis of gene expression. Science (Washington DC), 270: 484-487, 1995.
22. Kondoh, N., Schweinfest, C. W., Henderson, K. W., and Papas, T. S. Differential expression of S19 ribosomal protein, laminin-binding protein and human lymphocyte antigen class I messenger RNAs associated with colon carcinoma progression and differentiation. Cancer Res., 52: 791-796, 1992.
23. Komori, M., Nishio, K., Ohi, H., Kitada, M., and Kamataki, T. Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. J. Biochem., 105: 161-163, 1989.
24. Paterlini, P., Flejou, J. F., De Mitri, M. S., Pisi, E., Franco, D., and Brechot, C. Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters. J. Hepatol., 23: 47-52, 1995.
25. Tsutsumi, T., Ido, A., Nakao, K., Hamasaki, K., Kato, Y., Ohtsuru, A., Nakata, K., Tamaoki, T., and Nagataki, S. Reciprocal regulation of α-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology, 107: 499-504, 1994.
26. Pastorekova, S., Zavadova, Z., Kostal, M., Babusikova, O., and Zavada, J. A novel quasi-viral agent, MaTu, is a two-component system. Virology, 187: 620-626, 1992.
27. Raz, A., Meromsky, L., Zvibel, I., and Lotan, R. Transformation-related changes in the expression of endogenous cell lectins. Int. J. Cancer, 39: 353-360, 1987.
28. Gillenwater, A., Xu, X. C., el-Nagger, A. K., Clayman, G. L., and Lotan, R. Expression of galectins in head and neck squamous cell carcinoma. Head Neck, 18: 422-432, 1996.
29. Orlandi, F., Saggiorato, E., Pivano, G., Puligheddu, B., Termine, A., Cappia, S., De Giuli, P., and Angeli, A. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res., 15: 3015-3020, 1998.
30. Bresalier, R. S., Mazurek, N., Sternberg, L. R., Byrd, J. C., Yunker, C. K., Nangai-Makker, P., and Raz, A. Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin 3. Gastroenterology, 115: 287-296, 1998.
31. Yamaoka, K., Ohno, S., Kawasaki, H., and Suzuki, K. Overexpression of a β-galactoside binding protein causes transformation of BALB3T3 fibroblast cells. Biochem. Biophys. Res. Commun., 179: 272-279, 1991.
32. Inohara, H., Akahani, S., and Raz, A. Galectin-3 stimulates cell proliferation. Exp. Cell Res., 245: 294-302, 1998.
33. Rechreche, H., Mallo, G. V., Montalto, G., Dagorn, J. C., and Iovanna, J. L. Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer. Eur. J. Biochem., 248: 225-230, 1997.
34. Ritter, J. K., Chen, F., Sheen, Y. Y., Lubet, R. A., and Owens, I. S. Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. Biochemistry, 31: 3409-3414, 1992.
35. Jin, C-J., Miners, J. O., Lillywhite, K. J., and Mackenzie, P. I. cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferases 2B subfamily. Biochem. Biophys. Res. Commun., 194: 496-503, 1993.
36. Levesque, E., Beaulieu, M., Hum, D. W., and Belanger, A. Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics, 9: 207-216, 1999.
37. Strassburg, C. P., Manns, M. P., and Tukey, R. H. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res., 57: 2979-2985, 1997.
38. Burchell B., Baird, S., and Coughtrie, M. W. The role of xenobiotic glucuronidating enzymes in drug resistance of tumor tissues and cells. Princess Takamatsu Symp., 21: 263-275, 1990.
39. Barnard, G. F., Staniunas, R. J., Bao, S., Mafune, K., Steele, G. D., Gollan, J. L., and Chen, L. B. Increased expression of human ribosomal phosphoprotein P0 messenger RNA in hepatocellular carcinoma and colon carcinoma. Cancer Res., 52: 3067-3072, 1992.
40. Uchiumi, T., Traut, R. R., and Kominami, R. Monoclonal antibodies against acidic phosphoproteins P0, P1, and P2 of eukaryotic ribosomes as functional probe. J. Biol. Chem., 265: 89-95, 1990.
41. Lazaris-Karatzas, A., Montine, K. S., and Sonenberg, N. Malignant transformation by an eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature (Lond.), 345: 544-547, 1990.
42. Von Lindern, M., Fomerod, M., Van Baal, S., Jaegle, M., De Wit, T., Buijs, A., and Grosveld, G. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol. Cell. Biol., 12: 1687-1697, 1992.
43. Fu, G. K., Grosveld, G., and Markovitz, D. M. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc. Natl. Acad. Sci. USA, 94: 1811-1815, 1997.
44. Meyn, M. S., Lu-Kuo, J. M., and Herzing, L. B. K. Expression cloning of multiple human cDNAs that complement the phenotypic defects of ataxia-telangiectasia group D fibloblasts. Am. J. Hum. Genet., 53: 1206-1216, 1993.
45. Nakamura, Y. ATM: the P53 booster. Nat. Med., 4: 1231-1232, 1998.
46. Jones, J. I., and Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16: 3-34, 1995.
47. Lee, P. D., Suwanichkul, A., Depaolis, L. A., Snuggs, M. B., Morris, S. L., and Powell, D. R. Insulin-like growth factor (IGF) suppression of IGFBP-1 production: evidence for mediation by the type I IGF receptor. Regul. Pept., 48: 199-206, 1993.
48. Su, T. S., Liu, W. Y., Han, S. H., Jansen, M., Yang-Fen, T. L., P'eng, F. K., and Chou, C. K. Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res., 49: 1773-1777, 1989.
49. Babajiko, S., Tronche, F., and Groyer, A. Liver-specific expression of human insulinlike growth factor binding protein 1: functional role of transcription factor HNF1 in vivo. Proc. Natl. Acad. Sci. USA, 90: 272-276, 1993.
50. Lee, P. D. K., Giudice, L. C., Conover, C. A., and Powell, D. R. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med., 216: 319-357, 1997.
51. Tsai, T. F., Yauk, Y. K., Chou, C. K., Ting, L. P., Chang, C., Hu, C. P., Han, S. H., and Su, T. S. Evidence of autocrine regulation in human hepatoma cell lines. Biochem. Biophys. Res. Commun., 153: 39-45, 1988.
52. Hayman, E. G., Pierschbacher, M. D., and Rouslahti, E. Detachment of cells from culture substrate by soluble fibronectin peptides. J. Cell. Biol., 100: 1948-1954, 1985.
53. Jaskewickz, K., Chasen, M. R., and Robson, S. C. Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res., 13: 2229-2238, 1993.
54. Mao, M., Yu, M., Tong, J., Ye, J., Zhu, J., Huang, Q., Fu, G., Yu, L., Zhao, S., Waxman, S., Lanotte, M., Wang, Z., Tan, J., Chan, S., and Chen, Z. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc. Natl. Acad. Sci. USA, 93: 5910-5914, 1996.
55. Wan, Y. J., Cai, Y., and Magee, T. R. Retinoic acid differentially regulates retinoic acid receptor-mediated pathways in the Hep3B cell line. Exp. Cell Res., 238: 241-247, 1998.
56. Li, C., and Wan, Y. J. Differentiation and antiproliferation effects of retinoic acid receptor β in hepatoma cells. Cancer Lett., 124: 205-211, 1998.
57. Shan, X., Bourdeau, A., Rhoton, A., Wells, D. E., Cohen, E. H., Landgraf, B. E., and Palfree, R. G. Characterization and mapping to human chromosome 8q24.3 of Ly-6-related gene 9804 encoding an apparent homologue of mouse TSA-1. J. Immunol., 160: 197-208, 1998.
58. Kimura, Y., Furuhata, T., Urano, T., Hirata, K., Nakamura, Y., and Tokino, T. Genomic structure and chromosomal localization of GML (GPI-anchored moleculelike protein), a gene induced by p53. Genomics, 41: 477-480, 1997.
59. Gonzalez, F. J., and Lee, Y. Constitutive expression of hepatic P450 genes. FASEB J., 10: 1112-1117, 1996.
60. Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., and Cresteil, T. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem., 247: 625-634, 1997.
61. Schuetz, J. D., Beach, D. L., and Guzelian, P. S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4: 11-20, 1994.
62. Hashimoto, H., Nakagawa, T., Yokoi, T., Sawada, M., Itoh, S., and Kamataki, T. Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins. Cancer Res., 55: 787-791, 1995.
63. Mehmood, Z., Kelly, D. E., and Kelly, S. L. Cytochrome P450 3A4 mediated metabolism of 2,4-dichlorophenol. Chemosphere, 34: 2281-2291, 1997.
64. Shimada, T., and Guengerich, F. P. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. USA, 86: 462-465, 1989.
65. Li, Y., Yokoi, T., Katsuki, M., Wang, J. S., Groopman, J. D., and Kamataki, T. In vivo activation of aflatoxin B1 in C57BL/6N mice carring a human fetus-specific CYP3A7 gene. Cancer Res., 57: 641-645, 1997.
66. Yamada, A., Fujita, K., Yokoi, T., Muto, S., Suzuki, A., Gondo, Y., Katsuki, M., and Kamataki, T. In vitro detection of mutations induced by aflatoxin B1 using human CYP3A7/HITEC hybrid mice. Biochem. Biophys. Res. Commun., 250: 150-153, 1998.
67. Mace, K., Aguilar, F., Wang, J. S., Vautravers, P., Gomez-Lechon, M., Gonzalez, F. J., Groopman, J., Harris, C. C., and Pfeifer, A. M. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis (Lond.), 18: 1291-1297, 1997.
68. Morgan, E. T. Regulation of cytochromes P450 during inflammation and infection. Drug. Metab. Rev., 29: 1129-1188, 1997.